Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alector, Inc. (NASDAQ: ALEC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. Alector is a late-stage clinical biotechnology company focused on neurodegenerative diseases, and its filings offer detailed insight into clinical progress, financial performance, and corporate actions.
Investors can review Alector’s Form 8-K filings for material events such as quarterly financial results, restructuring plans, and leadership changes. For example, 8-K reports describe the announcement of second and third quarter financial results, the Phase 3 INFRONT-3 trial outcome for latozinemab (AL001) in FTD-GRN and the associated reduction in workforce, and the appointment of Neil Berkley as Chief Financial Officer while he continues as Chief Business Officer. These filings also outline estimated restructuring charges and separation arrangements for departing executives.
Beyond current reports, users can access periodic filings such as Forms 10-K and 10-Q (when available) to examine Alector’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and investment balances. For a company developing late-stage and preclinical programs in neurodegeneration, these documents are key to understanding funding runway, partnering structures, and portfolio priorities.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly grasp the implications of complex disclosures. The platform also makes it easier to track insider transaction reports on Form 4 and other ownership-related filings, so users can monitor how executives and major holders interact with ALEC shares. Use this page to navigate Alector’s regulatory history, from clinical trial updates to financial and governance events, with AI tools that streamline document review.
Alector, Inc. Schedule 13G/A summary: This amendment reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals (Peter Kolchinsky and Rajeev Shah) each beneficially own 0 shares of Alector common stock, representing 0.0% of the class as of the reporting date. The filing lists the reporting persons' principal business address at c/o RA Capital Management, 200 Berkeley Street, Boston, MA, and states the entities are Delaware partnerships while the individuals are U.S. citizens. The reporting persons expressly disclaim status as a group and confirm the securities were not acquired to influence control of the issuer. The filing incorporates a Joint Filing Agreement by reference.
Alector, Inc. (ALEC) submitted a Form 144 reporting a proposed sale of 76,446 common shares with an aggregate market value of $152,892.00, against 101,212,329 shares outstanding. The filing states the shares were acquired as restricted stock on 03/01/2023 and lists an approximate sale date of 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The notice also discloses a prior sale of 16,488 shares on 06/02/2025 for gross proceeds of $22,065.89. The signer represents there is no undisclosed material adverse information and includes standard Rule 144 attestations.
Insider transaction: On 06/20/2025, Alector, Inc. (ALEC) director Kristine Yaffe sold 1,000 shares of common stock at a price of $1.44 per share, according to a Form 4 filed with the SEC.
Following the sale, Yaffe’s direct beneficial ownership stands at 95,409 shares. No derivative security activity was reported, and the filing was signed on 06/23/2025 by attorney-in-fact Danielle Pasqualone.